ContextVision (CONTX) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue grew 2.8% year-over-year to SEK 34.1 million, driven by a sales push in Asia and strong interest in quantitative imaging and AI solutions.

• Full-year 2024 revenue was SEK 130.7 million, slightly below the prior year, reflecting a hesitant market but offset by strategic product launches and partnerships.

• Launched two new products at RSNA, generating strong customer interest in quantitative imaging and data quality.

• Progressed collaborations with OEMs and signed a partnership with the University of Washington to advance clinical development of focus venture products and AI-driven liver disease diagnostics.

• Share buyback of 1.2 million shares at NOK 6.5 per share, underlining a strong cash position.

Financial highlights

• Q4 revenue: SEK 34.1 million (up 2.8% year-over-year); full-year revenue: SEK 130.7 million (down 1.1%).

• Q4 adjusted EBITDA: SEK 11.4 million, margin 33.4%; full-year adjusted EBITDA: SEK 45.8 million, margin 35.1%.

• Q4 net result: SEK 6.4 million; full-year net result: SEK 24.7 million.

• Operating cash flow for Q4 at SEK 9.1 million; full-year operating cash flow at SEK 32.9 million.

• Year-end cash position at SEK 74.4 million.

Outlook and guidance

• Positive outlook for 2024 and anticipated growth in 2025, driven by strong momentum in quantitative imaging, new product launches, and recovery in the Chinese market.

• Ongoing collaborations and new partnerships expected to translate into future revenues.

• Cost base expected to remain higher than previous years but lower than Q4, as non-recurring costs subside.

• Continued investment in Data Quality and POCUS, targeting up to 10% of revenues for R&D in digital biomarkers.